Patents Assigned to Genexine Inc.
-
Patent number: 11883479Abstract: A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection include administering a combination of a HPV-specific fusion protein and an immunomodulatory agent.Type: GrantFiled: April 26, 2021Date of Patent: January 30, 2024Assignees: GENEXINE, INC., MSD International GmbHInventors: Young Chul Sung, Jung Won Woo, Jong Sup Park, Jin Won Youn
-
Publication number: 20240018205Abstract: The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.Type: ApplicationFiled: June 1, 2023Publication date: January 18, 2024Applicant: GENEXINE, INC.Inventors: Moon Cheol KANG, Young Woo CHOI, Donghoon CHOI, Young Chul SUNG
-
Publication number: 20230398184Abstract: The present disclosure relates to methods of promoting the mobilization of HSCs to the peripheral blood with an IL-7 protein. In some aspects, the method further comprises administering an additional agent, such as G-CSF and/or AMD3100. In some aspects, the methods disclosed herein are useful in treating a disease or disorder associated with an abnormality of a hematopoietic process.Type: ApplicationFiled: October 25, 2021Publication date: December 14, 2023Applicants: NeoImmuneTech, Inc., GENEXINE, INC., POSTECH Academy-Industry FoundationInventors: Donghoon CHOI, Young Chul SUNG, Seung-Woo LEE, Sora KIM, Young-Min KIM
-
Publication number: 20230279069Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v%; and (d) a surfactant with a concentration of 0.05 to 6 w/v%. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.Type: ApplicationFiled: November 8, 2022Publication date: September 7, 2023Applicant: Genexine, Inc.Inventors: Donghoon CHOI, Changyong Eun, Seong Hoon Jeong, Jun Yeul LIM
-
Patent number: 11708399Abstract: The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.Type: GrantFiled: December 2, 2016Date of Patent: July 25, 2023Assignee: GENEXINE, INC.Inventors: Moon Cheol Kang, Young Woo Choi, Donghoon Choi, Young Chul Sung
-
Publication number: 20230123454Abstract: The present invention relates to a fusion protein including PD-L1 protein and a modified immunoglobulin Fc region and use thereof, and since the fusion protein has significantly higher purity and production yield compared to the existing fusion protein, has a high binding affinity to PD-1, reduces the proliferation of activated T cells, inhibits the generation of cytokines generated by activated T cells, and has an effect of inhibiting the infiltration of T cells or macrophages into tissues, it can be effectively used in the treatment of immune diseases.Type: ApplicationFiled: January 6, 2021Publication date: April 20, 2023Applicant: Genexine, Inc.Inventors: Young Chul SUNG, Eun Ju SHIN, Yuri HWANG, Sung Hee LEE
-
Publication number: 20230015320Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.Type: ApplicationFiled: June 13, 2022Publication date: January 19, 2023Applicant: GENEXINE, INC.Inventors: Moon Cheol KANG, Young Woo CHOI, Donghoon CHOI, Young Chul SUNG
-
Patent number: 11548927Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.Type: GrantFiled: November 2, 2016Date of Patent: January 10, 2023Assignee: GENEXINE, INC.Inventors: Donghoon Choi, Changyong Eun, Seong Hoon Jeong, Jun Yeul Lim
-
Patent number: 11524054Abstract: The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.Type: GrantFiled: January 8, 2016Date of Patent: December 13, 2022Assignees: GENEXINE, INC., GREEN CROSS CORPORATIONInventors: Sang-In Yang, Jung-Won Woo, Se Hwan Yang, Young Chul Sung, Doo Hong Park, Min Woo Kim
-
Publication number: 20220305086Abstract: A method for increasing a lymphocyte count in a subject in need thereof including administering to the subject (i) a modified interleukin-7 of the following formula (I): A?IL-7 wherein A is an oligopeptide consisting of 1 to 10 amino acid residues, and the IL-7 is a polypeptide which is capable of binding to IL-7 receptor; or (ii) an interleukin-7 fusion protein comprising (a) the modified interleukin-7, (b) a second domain containing an oligopeptide having 1 to 10 amino acid residues consisting of methionine, glycine, or a combination thereof; and (c) a third domain which prolongs the half-life of the interleukin-7 fusion protein.Type: ApplicationFiled: September 4, 2020Publication date: September 29, 2022Applicants: GENEXINE, INC., NEOIMMUNE TECH, INC.Inventors: Young Chul SUNG, Jung Won WOO, MinK yu HEO, Sang In YANG, SeHwan YANG
-
Patent number: 11357827Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.Type: GrantFiled: November 30, 2016Date of Patent: June 14, 2022Assignee: Genexine, Inc.Inventors: Moon Cheol Kang, Young Woo Choi, Donghoon Choi, Young Chul Sung
-
Publication number: 20220096589Abstract: A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving treatment of cervical tumor caused by HPV infection are also disclosed. The methods include administering a polynucleotide encoding an E6/E7 fusion protein to a subject suffering from cervical tumor caused by HPV. The cervical tumor may be squamous cell carcinoma (SCC), adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor (NET), glassy cell carcinoma, villoglandular adenocarcinoma (VGA), non-carcinoma malignancies, melanoma, lymphoma, or cervical intraepithelial neoplasia (CIN).Type: ApplicationFiled: August 27, 2021Publication date: March 31, 2022Applicant: GENEXINE, INC.Inventors: Hyun-Tak JIN, Hye Seong LIM, You Suk SUH, Eun Joo NAM
-
Publication number: 20220008515Abstract: The present disclosure relates to methods of treating a cancer (or a tumor) with an IL-7 protein in combination with an immune checkpoint inhibitor, such as a PD-1 antagonist (e.g., anti-PD-1 antibody) or a CTLA-4 antagonist (e.g., anti-CTLA-4 antibody).Type: ApplicationFiled: November 15, 2019Publication date: January 13, 2022Applicants: NeoImmuneTech, Inc., Genexine, Inc.Inventors: Seung-Woo LEE, Ji-Hae KIM, Saet-byeol JO, Han Wook PARK, Donghoon CHOI, Byung Ha LEE, Young Chul SUNG, Se Hwan YANG
-
Publication number: 20210330779Abstract: A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection include administering a combination of a HPV-specific fusion protein and an immunomodulatory agent.Type: ApplicationFiled: April 26, 2021Publication date: October 28, 2021Applicant: GENEXINE, INC.Inventor: Young Chul SUNG
-
Publication number: 20210324027Abstract: Provided are a modified IL-7 polypeptide and a fusion protein containing the modified IL-7 polypeptide. The fusion protein of the modified IL-7 includes: a first domain containing an interleukin-7 polypeptide; a second domain containing an oligopeptide having 1 to 10 amino acid residues (with proviso that the second domain excludes the oligopeptide consisting of methionine and/or glycine); and (c) a third domain which prolongs the half-life of the IL-7 fusion protein. The modified IL-7 polypeptide is composed of the (a) first domain and the (b) second domain. The modified IL-7 polypeptide and the fusion protein are expressed in a higher yield than the wild-type IL-7 and shows increased stability.Type: ApplicationFiled: April 16, 2021Publication date: October 21, 2021Applicants: GENEXINE, INC., NEOIMMUNE TECH, INC.Inventors: Young Chul SUNG, Gwang Hyeon GWON, So Young CHOI, Hyi Jeong JI, Dong Hoon CHOI
-
Patent number: 11135262Abstract: This invention relates to the treatment of cervical tumor caused by human papillomavirus (HPV) infection. In particular, the invention provides methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection using a polynucleotide encoding an E6/E7 fusion protein.Type: GrantFiled: August 14, 2015Date of Patent: October 5, 2021Assignee: GENEXINE, INC.Inventors: Hyun-Tak Jin, Hye Seong Lim, You Suk Suh, Eun Joo Nam
-
Patent number: 11041007Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.Type: GrantFiled: December 13, 2018Date of Patent: June 22, 2021Assignee: GENEXINE, INC.Inventors: Se Hwan Yang, Donghoon Choi, Hye Seong Lim
-
Patent number: 10844104Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.Type: GrantFiled: June 5, 2018Date of Patent: November 24, 2020Assignee: GENEXINE, INC.Inventors: Se Hwan Yang, Donghoon Choi, Hye Seong Lim
-
Publication number: 20200282021Abstract: A method of regulating blood glucose level and/or treating a diabetes is disclosed. The method includes administering a fusion peptide of a GLP-1 peptide and an Fc region. The Fc region is a hybrid Fc region containing a hinge region, a CH2 domain, and a CH3 domain from the N-terminal to the C-terminal direction, wherein the hinge region comprises a human IgD hinge region, the CH2 domain comprises a part of the amino acid residues of CH2 domain of human IgD and human IgG4, and the CH3 domain comprises a part of the amino acid residues of the human IgG4 CH3 domain, and has glycosylation at the IgD hinge region. The fusion peptide shows reduced side effects such as vomiting, nausea, and/or heart rate increase.Type: ApplicationFiled: March 9, 2020Publication date: September 10, 2020Applicant: GENEXINE, INC.Inventors: Young Chul SUNG, Mi Sun Byun, In-Bok An
-
Patent number: 10538569Abstract: The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs.Type: GrantFiled: December 31, 2015Date of Patent: January 21, 2020Assignee: GENEXINE, INC.Inventors: Young Chul Sung, Se Hwan Yang, Mi Sun Byun, Sang In Yang, Eun Ju Shin